東アジアの製薬市場：日本、台湾、韓国...市場調査レポートについてご紹介

1. Report Overview
1.1 East Asian Pharmaceutical Market Overview
1.2 East Asian Pharmaceutical Market Report Segmentation
1.3 Why You Should Read This Report?
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
1.11 Exchange Rates

2. Introduction to the East Asian Pharmaceutical Market
2.1 National Market Definitions
2.1.1 Japan
2.1.2 Taiwan
2.1.3 Korea
2.2 Other Pharmaceutical Market Definitions
2.2.1 Originator Drugs
2.2.2 Generic Drugs (Generics)
2.2.3 OTC (Over-The-Counter)
2.2.4 Biosimilars
2.3 Introduction to the Global Pharmaceutical Market: A Brief Overview
2.4 Pharmaceutical Approval Regulations
2.4.1 Japan
2.4.2 Taiwan
2.4.3 Korea
2.5 The East Asian Pharmaceutical Market Forecast, 2016-2026

3. The Japanese Pharmaceutical Market
3.1 The Japanese Healthcare System
3.1.1 Costing and Healthcare Delivery
3.1.2 Increasing Generic Penetration: A Matter of Government Policy
3.1.3 Health Technology Assessments
3.2 The Japanese Pharmaceutical Market 2014 and 2015
3.2.1 The Japanese Pharmaceutical Market Forecast, 2016-2026
3.3 The Japanese Pharmaceutical Market 2016-2026: Submarket Shares
3.4 The Japanese Generic Drugs Market 2014
3.4.1 Public Perception Of Generics In Japan
3.4.2 The Japanese Generic Drugs Market Forecast, 2016-2026
3.5 The Japanese Originator Drugs Market 2014
3.5.1 The Japanese Originator Drugs Market Forecast, 2016-2026
3.6 The Japanese OTC Drugs Market 2014 and 2015
3.6.1 The Japanese OTC Drugs Market Forecast, 2016-2026
3.7 The Japanese Biosimilar Drugs Market 2014 and 2015
3.7.1 The Japanese Biosimilar Drugs Market Forecast, 2016-2026

4. Qualitative Analysis of the Japanese Pharmaceutical Market
4.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026
4.1.1 Strengths
4.1.1.1 Affinity for Branded Products Helping Maintain Revenues
4.1.1.2 High Utilisation of Healthcare Facilities
4.1.1.3 Ageing Population Driving Demand
4.1.2 Weaknesses
4.1.2.1 Reduced Profit Margins Due to Government Pricing
4.1.2.2 Increasing Penetration of Generics Eroding Off-Patent Originator Revenues
4.1.2.3 Restrictions of the OTC Market and Low Consumer Desire
4.1.3 Opportunities
4.1.3.1 Ageing Population Resulting in Increased Demand For High-End Pharmaceuticals
4.1.3.2 New Regulation Allowing for Expansion of the Regenerative Medicine Sector – Sakigake Reforms
4.1.3.3 Increased Trade Opportunities via the Trans-Pacific Partnership (TPP)
4.1.4 Threats
4.1.4.1 Possible Funding Issues Due to Demographics
4.1.4.2 Expanded Use of Biosimilars May Erode Pharmaceutical Market Revenues
4.2 Porter’s Five Forces Analysis of the Japanese Pharmaceutical Market
4.2.1 Rivalry Among Competitors [Medium]
4.2.2 Threat of New Entrants [Medium]
4.2.3 Power of Buyers [Medium]
4.2.4 Power of Suppliers [Medium]
4.2.5 Threat of Substitutes [Medium]
4.3 Leading Japanese Domestic Pharmaceutical Companies
4.3.1 Takeda
4.3.1.1 Litigation Regarding ACTOS in the US
4.3.2 Astellas Pharma
4.3.3 Otsuka Pharmaceuticals
4.3.4 Daiichi Sankyo
4.3.5 Eisai Co.

5. The Taiwanese Pharmaceutical Market
5.1 The Taiwanese Healthcare System
5.1.1 Costing and Healthcare Delivery
5.1.2 Health Technology Assessments
5.2 The Taiwanese Pharmaceutical Market 2014 and 2015
5.2.1 The Taiwanese Pharmaceutical Market Forecast, 2016-2026
5.3 The Taiwanese Pharmaceutical Market 2016-2026: Submarket Shares
5.4 The Taiwanese Generic Drugs Market 2014 and 2015
5.4.1 The Taiwanese Generic Drugs Market Forecast, 2016-2026
5.5 The Taiwanese Originator Drugs Market 2014 and 2015
5.5.1 The Taiwanese Originator Drugs Market Forecast, 2016-2026
5.6 The Taiwanese OTC Drugs Market 2014 and 2015
5.6.1 The Taiwanese OTC Drugs Market Forecast, 2016-2026
5.7 The Taiwanese Biosimilar Drugs Market 2014 and 2015
5.7.1 The Taiwanese Biosimilar Drugs Market Forecast, 2016-2026

6. Qualitative Analysis of the Taiwanese Pharmaceutical Market
6.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026
6.1.1 Strengths
6.1.1.1 Stable Levels of NHI Funding
6.1.1.2 High Trust and Utilisation of Healthcare Facilities
6.1.1.3 Increasingly Aged Population
6.1.2 Weaknesses
6.1.2.1 Strong Presence of Traditional Medicines
6.1.2.2 Political Isolation and Lack of Bilateral Trade Deals
6.1.3 Opportunities
6.1.3.1 Ageing Population and Associated Pharmaceutical Demand Set to Increase
6.1.3.2 Newly Elected Government Promises Support for Pharmaceutical and Biotechnology Industries
6.1.3.3 The Promotion of Taiwan as a Destination for Medical Tourism
6.1.4 Threats
6.1.4.1 The Influence of China on Taiwanese International Relations
6.1.4.2 Rapid Growth of Pharmaceutical Markets in Rival Asian Countries
6.2 Porter’s Five Forces Analysis of the Taiwanese Pharmaceutical Market
6.2.1 Rivalry Among Competitors [Medium]
6.2.2 Threat of New Entrants [Low]
6.2.3 Power of Buyers [High]
6.2.4 Power of Suppliers [Low]
6.2.5 Threat of Substitutes [High]
6.3 Leading Taiwanese Pharmaceutical Companies
6.3.1 Standard Chem and Pharma Co. (SCP)
6.3.2 Chunghwa Chemical and Pharmaceutical Co.
6.3.3 Yung Shin Pharmaceutical Industry
6.3.4 TWi Biotechnology
6.3.5 OBI Pharmaceutical

7. The Korean Pharmaceutical Market
7.1 The Korean Healthcare System
7.1.1 Costing and Healthcare Delivery
7.2 The Korean Pharmaceutical Market 2014 and 2015
7.2.1 The Korean Pharmaceutical Market Forecast, 2016-2026
7.3 The Korean Pharmaceutical Market 2016-2026: Submarket Shares
7.4 The Korean Generic Drugs Market 2014 and 2015
7.4.1 Pharmaceutical Price Controls and Measures Being Implemented In South Korea
7.4.2 KORUS FTA: The Free Trade Agreement Between South Korea And The US
7.4.3 The Free Trade Agreement between Korea And The European Union
7.4.4 The Korean Generic Drugs Market Forecast, 2016-2026
7.5 The Korean Originator Drugs Market 2014 and 2015
7.5.1 The Korean Originator Drugs Market Forecast, 2016-2026
7.6 The Korean OTC Drugs Market 2014 and 2015
7.6.1 The Korean OTC Drugs Market Forecast, 2016-2026
7.7 The Korean Biosimilar Drugs Market 2014 and 2015
7.7.1 The Korean Biosimilar Drugs Market Forecast, 2016-2026

8. Qualitative Analysis of the Taiwanese Pharmaceutical Market
8.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026
8.1.1 Strengths
8.1.1.1 Increasing Strength of Domestic Companies
8.1.1.2 Most Rapidly Ageing Population in the World
8.1.1.3 High Rate of OTC Use Among Population
8.1.2 Weaknesses
8.1.2.1 Funding for Healthcare Becoming Stretched and Pharmaceutical Pricing Pressure
8.1.2.2 Export Prices Based on Domestic Reimbursement
8.1.3 Opportunities
8.1.3.1 Ageing Population Will Result in Increased Expenditure
8.1.3.2 Increasing Level of International Sales for Domestic Companies
8.1.3.3 Korea has Registered Interest in Joining the TPP
8.1.4 Threats
8.1.4.1 Korea is Highly Reliant on Other Countries for its Economic Growth
8.1.4.2 Continued Pricing Pressure
8.2 Porter’s Five Forces Analysis of the Korean Pharmaceutical Market
8.2.1 Rivalry Among Competitors [Medium]
8.2.2 Threat of New Entrants [Medium]
8.2.3 Power of Buyers [High]
8.2.4 Power of Suppliers [Low]
8.2.5 Threat of Substitutes [High]
8.3 Leading Korean Pharmaceutical Companies
8.3.1 Daewoong Pharmaceutical Co.
8.3.2 Samsung Bioepis
8.3.3 Celltrion

9. Interviews
9.1 Interview with Sawai Pharmaceuticals, Tokyo, Japan
9.1.1 State of the Pharmaceutical Market in Japan
9.1.2 Current Challenges Facing the Market
9.1.3 Area with Highest Potential for Growth
9.1.4 Effect of Government Policy
9.1.5 Effect of the TPP
9.1.6 Opinions on the Taiwanese and Korean Pharmaceutical Markets

10. Conclusions
10.1 The East Asian Pharmaceutical Market
10.1.1 Ageing Population and Increased Healthcare Spending Pressure
10.1.2 Slowing Economic Growth
10.2 The Japanese Pharmaceutical Market
10.3 The Taiwanese Pharmaceutical Market
10.4 The Korean Pharmaceutical Market